Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06204-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Francesca Palandri und 29 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. francesca.palandri@unibo.it. Hauptthemen laut MEDLINE: Calreticulin, Mutation, Primary Myelofibrosis, Pyrazoles. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.
Abstract (Originalsprache)
Calreticulin ( CALR ) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with JAK2 -inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the CALR mutant clone have entered clinical investigation. To collect information on efficacy and safety of ruxolitinib in CALR -mutated patients, we report a sub-analysis of the “RUX-MF” (NCT06516406) study, comprising 135 CALR -mutated and 786 JAK2 -mutated ruxolitinib-treated patients. Compared to JAK2 -mutated patients, CALR -mutated patients started ruxolitinib with a more severe disease (higher peripheral blast counts, lower hemoglobin levels and worse marrow fibrosis) and after a longer median time from diagnosis (2.6 versus 0.7 years, p < 0.001). At 6 months, spleen responses were numerically inferior in CALR -mutated patients, who also had significantly lower rates of symptom responses (56.1% versus 66.7%, p = 0.04).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. francesca.palandri@unibo.it.
- Institute of Hematology "L. and A. Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, Bologna (BO), 40138, Italy. francesca.palandri@unibo.it.
- Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
- Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica Delle Marche, Ancona, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- University Hematology Division, Città della Salute e Della Scienza Hospital, Torino, Italy.
Förderung
- Alma Mater Studiorum - Università di Bologna
Zitieren
APA
Palandri, F., Branzanti, F., Morsia, E., Dedola, A., Benevolo, G., Tiribelli, M., Beggiato, E., Farina, M., Martino, B., Caocci, G., Pugliese, N., Tieghi, A., Crugnola, M., Binotto, G., Cavazzini, F., Abruzzese, E., Isidori, A., Scalzulli, E., D'Agostino, D., …, & Bonifacio, M. (2025). Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy. Annals of Hematology. https://doi.org/10.1007/s00277-025-06204-5
Vancouver
Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M, et al. Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy. Annals of Hematology. 2025. doi:10.1007/s00277-025-06204-5
BibTeX
@article{Palandri2025,
author = {Palandri, Francesca and Branzanti, Filippo and Morsia, Erika and Dedola, Alessandra and Benevolo, Giulia and Tiribelli, Mario and Beggiato, Eloise and Farina, Mirko and Martino, Bruno and Caocci, Giovanni and Pugliese, Novella and Tieghi, Alessia and Crugnola, Monica and Binotto, Gianni and Cavazzini, Francesco and Abruzzese, Elisabetta and Isidori, Alessandro and Scalzulli, Emilia and D'Agostino, Domenico and Caserta, Santino and Nardo, Antonella and Lemoli, Roberto Massimo and Cilloni, Daniela and Bocchia, Monica and Pane, Fabrizio and Heidel, Florian H and Palumbo, Giuseppe A and Breccia, Massimo and Elli, Elena M and Bonifacio, Massimiliano},
title = {Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06204-5}
}
EUVIMED